Literature DB >> 17261715

Preconditioning reprograms the response to ischemic injury and primes the emergence of unique endogenous neuroprotective phenotypes: a speculative synthesis.

Mary P Stenzel-Poore1, Susan L Stevens, Jeffrey S King, Roger P Simon.   

Abstract

Ischemic tolerance in the brain, in which sub-threshold insults increase resistance to subsequent injurious ischemia, is a powerful adaptive defense that involves an endogenous program of neuroprotection. Emerging evidence from genomic studies suggests diverse stimuli that trigger preconditioning achieve neuroprotection through a common process which depends on a fundamental reprogramming of the response to injury. Such reprogramming of the genomic response to injury leads to the induction of novel neuroprotective pathways not ordinarily found in the setting of ischemia. Genomic studies also indicate that the nature of the preconditioning stimulus (eg, brief ischemia or endotoxin [lipopolysaccharide]) dictates the phenotype of neuroprotection, a phenotype that parallels protective adaptations also found in certain physiological conditions where the preconditioning stimulus exists at levels that can induce injury. The idea that preconditioning leads to a fundamental reprogramming event that confers neuroprotection is a novel and important concept in the field of ischemic tolerance. Moreover, the view that distinct preconditioning stimuli confer neuroprotection via effectors that differ according to the nature of the preconditioning stimulus offers promise that multiple, nonoverlapping pathways may be discovered as novel neuroprotective therapies.

Entities:  

Mesh:

Year:  2007        PMID: 17261715     DOI: 10.1161/01.STR.0000251444.56487.4c

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  94 in total

1.  Preconditioning induces sustained neuroprotection by downregulation of adenosine 5'-monophosphate-activated protein kinase.

Authors:  V R Venna; J Li; S E Benashski; S Tarabishy; L D McCullough
Journal:  Neuroscience       Date:  2011-11-18       Impact factor: 3.590

Review 2.  MicroRNA in ischemic stroke etiology and pathology.

Authors:  Cameron Rink; Savita Khanna
Journal:  Physiol Genomics       Date:  2010-09-14       Impact factor: 3.107

3.  Expression profiling the microRNA response to epileptic preconditioning identifies miR-184 as a modulator of seizure-induced neuronal death.

Authors:  Ross C McKiernan; Eva M Jimenez-Mateos; Takanori Sano; Isabella Bray; Raymond L Stallings; Roger P Simon; David C Henshall
Journal:  Exp Neurol       Date:  2012-07-05       Impact factor: 5.330

Review 4.  Neuroprotection for ischemic stroke: past, present and future.

Authors:  Myron D Ginsberg
Journal:  Neuropharmacology       Date:  2008-03-04       Impact factor: 5.250

Review 5.  Preconditioning and tolerance against cerebral ischaemia: from experimental strategies to clinical use.

Authors:  Ulrich Dirnagl; Kyra Becker; Andreas Meisel
Journal:  Lancet Neurol       Date:  2009-04       Impact factor: 44.182

6.  Regulation of gene expression in ischemic preconditioning in the brain.

Authors:  Tuo Yang; Qianqian Li; Feng Zhang
Journal:  Cond Med       Date:  2017-12-15

7.  Preconditioning the human brain: practical considerations for proving cerebral protection.

Authors:  Sebastian Koch
Journal:  Transl Stroke Res       Date:  2010-09       Impact factor: 6.829

8.  HuR function and translational state analysis following global brain ischemia and reperfusion.

Authors:  Jeffrey J Szymanski; Haihui Wang; Jill T Jamison; Donald J DeGracia
Journal:  Transl Stroke Res       Date:  2013-08-02       Impact factor: 6.829

Review 9.  Neuroimmune Response in Ischemic Preconditioning.

Authors:  Ashley McDonough; Jonathan R Weinstein
Journal:  Neurotherapeutics       Date:  2016-10       Impact factor: 7.620

10.  Effect of noradrenalin and EGb 761 pretreatment on the ischemia-reperfusion injured spinal cord neurons in rabbits.

Authors:  Eva Mechírová; Iveta Domoráková; Marianna Danková; Viera Danielisová; Jozef Burda
Journal:  Cell Mol Neurobiol       Date:  2009-03-17       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.